Elisa,

Sorry, but the below question was inadvertently omitted from the earlier IR. Additionally, the review team has requested a response to this question by Friday, July 30, 2021.

Please calculate the cumulative incidence rates of vaccine and placebo arms at Day 57 and Day 224 and estimate the Risk Difference and Risk Ratio with their 95% CI.

Regards,

Mike

- Please confirm receipt of this e-mail and let us know if you have any questions.

Hi Mike,

I confirm receipt.

Best regards,
Elisa

From: Smith, Michael (CBER) <Michael.Smith2@fda.hhs.gov>
Sent: Tuesday, July 27, 2021 10:01 AM
To: Harkins Tull, Elisa <Elisa.HarkinsTull@pfizer.com>; Aghajani Memar, Neda <Neda.AghajaniMemar@pfizer.com>; Devlin, Carmel M <Carmel.Devlin@pfizer.com>
Cc: Naik, Ramachandra <Ramachandra.Naik@fda.hhs.gov>; Gottschalk, Laura <Laura.Gottschalk@fda.hhs.gov>
Subject: [EXTERNAL] STN 125742.0: IR RE assessment of vaccine effectiveness

Elisa,

The review team has the below Information Request for Pfizer and BioNTech Manufacturing GmbH.

1. Regarding the cumulative incidence rates, please calculate vaccine effectiveness with confidence intervals during the two intervals of interest separately from days 35-91 (i.e., 8 weeks of observation after dose 2) and from days 91-224 (more prolonged follow up post vaccination series).

2. We also request assessment of vaccine effectiveness during a time period that is entirely further out from vaccination (e.g., starting at 4 months post-dose 2). We acknowledge though that at some point unblinding and placebo cross-over started, and there may have been differential loss between the two groups from blinded follow-up that could introduce bias and/or confound the analyses.

Please respond within one week from today.

Regards,

Mike

- Please confirm receipt of this e-mail and let us know if you have any questions.

Mike Smith, Ph.D.
Captain, USPHS
THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS
ADDRESS AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND
PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a
person authorized to deliver the document to the addressee, you are hereby
notified that any review, disclosure, dissemination, copying, or other action
based on the content of this communication is not authorized. If you have
received this document in error, please immediately notify the sender
immediately by e-mail or phone.